Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities

Reeva Aggarwal, Jingwei Lu, Suman Kanji, Matthew Joseph, Manjusri Das, Garrett J. Noble, Brooke K. McMichael, Sudha Agarwal, Richard T. Hart, Zongyang Sun, Beth S. Lee, Thomas J. Rosol, Rebecca Jackson, Hai Quan Mao, Vincent J. Pompili, Hiranmoy Das

Research output: Contribution to journalArticle

28 Citations (Scopus)

Abstract

Background: Osteoporosis is a bone disorder associated with loss of bone mineral density and micro architecture. A balance of osteoblasts and osteoclasts activities maintains bone homeostasis. Increased bone loss due to increased osteoclast and decreased osteoblast activities is considered as an underlying cause of osteoporosis. Methods and Findings: The cures for osteoporosis are limited, consequently the potential of CD34+ cell therapies is currently being considered. We developed a nanofiber-based expansion technology to obtain adequate numbers of CD34+ cells isolated from human umbilical cord blood, for therapeutic applications. Herein, we show that CD34+ cells could be differentiated into osteoblastic lineage, in vitro. Systemically delivered CD34+ cells home to the bone marrow and significantly improve bone deposition, bone mineral density and bone micro-architecture in osteoporotic mice. The elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-1 in serum parallel the improvements in bone micro-architecture. Furthermore, CD34+ cells improved osteoblast activity and concurrently impaired osteoclast differentiation, maturation and functionality. Conclusions: These findings demonstrate a novel approach utilizing nanofiber-expanded CD34+ cells as a therapeutic application for the treatment of osteoporosis.

Original languageEnglish (US)
Article numbere39365
JournalPloS one
Volume7
Issue number6
DOIs
StatePublished - Jun 18 2012

Fingerprint

umbilical cord
Inbred NOD Mouse
SCID Mice
osteoporosis
Fetal Blood
Osteoporosis
Bone
Blood
bones
Bone and Bones
osteoclasts
osteoblasts
blood
mice
Osteoclasts
Osteoblasts
nanofibers
Nanofibers
bone density
cells

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Agricultural and Biological Sciences(all)
  • General

Cite this

Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities. / Aggarwal, Reeva; Lu, Jingwei; Kanji, Suman; Joseph, Matthew; Das, Manjusri; Noble, Garrett J.; McMichael, Brooke K.; Agarwal, Sudha; Hart, Richard T.; Sun, Zongyang; Lee, Beth S.; Rosol, Thomas J.; Jackson, Rebecca; Mao, Hai Quan; Pompili, Vincent J.; Das, Hiranmoy.

In: PloS one, Vol. 7, No. 6, e39365, 18.06.2012.

Research output: Contribution to journalArticle

Aggarwal, R, Lu, J, Kanji, S, Joseph, M, Das, M, Noble, GJ, McMichael, BK, Agarwal, S, Hart, RT, Sun, Z, Lee, BS, Rosol, TJ, Jackson, R, Mao, HQ, Pompili, VJ & Das, H 2012, 'Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities', PloS one, vol. 7, no. 6, e39365. https://doi.org/10.1371/journal.pone.0039365
Aggarwal, Reeva ; Lu, Jingwei ; Kanji, Suman ; Joseph, Matthew ; Das, Manjusri ; Noble, Garrett J. ; McMichael, Brooke K. ; Agarwal, Sudha ; Hart, Richard T. ; Sun, Zongyang ; Lee, Beth S. ; Rosol, Thomas J. ; Jackson, Rebecca ; Mao, Hai Quan ; Pompili, Vincent J. ; Das, Hiranmoy. / Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities. In: PloS one. 2012 ; Vol. 7, No. 6.
@article{ca0fd663a33f4413ba25155c8d182fcc,
title = "Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities",
abstract = "Background: Osteoporosis is a bone disorder associated with loss of bone mineral density and micro architecture. A balance of osteoblasts and osteoclasts activities maintains bone homeostasis. Increased bone loss due to increased osteoclast and decreased osteoblast activities is considered as an underlying cause of osteoporosis. Methods and Findings: The cures for osteoporosis are limited, consequently the potential of CD34+ cell therapies is currently being considered. We developed a nanofiber-based expansion technology to obtain adequate numbers of CD34+ cells isolated from human umbilical cord blood, for therapeutic applications. Herein, we show that CD34+ cells could be differentiated into osteoblastic lineage, in vitro. Systemically delivered CD34+ cells home to the bone marrow and significantly improve bone deposition, bone mineral density and bone micro-architecture in osteoporotic mice. The elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-1 in serum parallel the improvements in bone micro-architecture. Furthermore, CD34+ cells improved osteoblast activity and concurrently impaired osteoclast differentiation, maturation and functionality. Conclusions: These findings demonstrate a novel approach utilizing nanofiber-expanded CD34+ cells as a therapeutic application for the treatment of osteoporosis.",
author = "Reeva Aggarwal and Jingwei Lu and Suman Kanji and Matthew Joseph and Manjusri Das and Noble, {Garrett J.} and McMichael, {Brooke K.} and Sudha Agarwal and Hart, {Richard T.} and Zongyang Sun and Lee, {Beth S.} and Rosol, {Thomas J.} and Rebecca Jackson and Mao, {Hai Quan} and Pompili, {Vincent J.} and Hiranmoy Das",
year = "2012",
month = "6",
day = "18",
doi = "10.1371/journal.pone.0039365",
language = "English (US)",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

TY - JOUR

T1 - Human umbilical cord blood-derived CD34+ cells reverse osteoporosis in NOD/SCID mice by altering osteoblastic and osteoclastic activities

AU - Aggarwal, Reeva

AU - Lu, Jingwei

AU - Kanji, Suman

AU - Joseph, Matthew

AU - Das, Manjusri

AU - Noble, Garrett J.

AU - McMichael, Brooke K.

AU - Agarwal, Sudha

AU - Hart, Richard T.

AU - Sun, Zongyang

AU - Lee, Beth S.

AU - Rosol, Thomas J.

AU - Jackson, Rebecca

AU - Mao, Hai Quan

AU - Pompili, Vincent J.

AU - Das, Hiranmoy

PY - 2012/6/18

Y1 - 2012/6/18

N2 - Background: Osteoporosis is a bone disorder associated with loss of bone mineral density and micro architecture. A balance of osteoblasts and osteoclasts activities maintains bone homeostasis. Increased bone loss due to increased osteoclast and decreased osteoblast activities is considered as an underlying cause of osteoporosis. Methods and Findings: The cures for osteoporosis are limited, consequently the potential of CD34+ cell therapies is currently being considered. We developed a nanofiber-based expansion technology to obtain adequate numbers of CD34+ cells isolated from human umbilical cord blood, for therapeutic applications. Herein, we show that CD34+ cells could be differentiated into osteoblastic lineage, in vitro. Systemically delivered CD34+ cells home to the bone marrow and significantly improve bone deposition, bone mineral density and bone micro-architecture in osteoporotic mice. The elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-1 in serum parallel the improvements in bone micro-architecture. Furthermore, CD34+ cells improved osteoblast activity and concurrently impaired osteoclast differentiation, maturation and functionality. Conclusions: These findings demonstrate a novel approach utilizing nanofiber-expanded CD34+ cells as a therapeutic application for the treatment of osteoporosis.

AB - Background: Osteoporosis is a bone disorder associated with loss of bone mineral density and micro architecture. A balance of osteoblasts and osteoclasts activities maintains bone homeostasis. Increased bone loss due to increased osteoclast and decreased osteoblast activities is considered as an underlying cause of osteoporosis. Methods and Findings: The cures for osteoporosis are limited, consequently the potential of CD34+ cell therapies is currently being considered. We developed a nanofiber-based expansion technology to obtain adequate numbers of CD34+ cells isolated from human umbilical cord blood, for therapeutic applications. Herein, we show that CD34+ cells could be differentiated into osteoblastic lineage, in vitro. Systemically delivered CD34+ cells home to the bone marrow and significantly improve bone deposition, bone mineral density and bone micro-architecture in osteoporotic mice. The elevated levels of osteocalcin, IL-10, GM-CSF, and decreased levels of MCP-1 in serum parallel the improvements in bone micro-architecture. Furthermore, CD34+ cells improved osteoblast activity and concurrently impaired osteoclast differentiation, maturation and functionality. Conclusions: These findings demonstrate a novel approach utilizing nanofiber-expanded CD34+ cells as a therapeutic application for the treatment of osteoporosis.

UR - http://www.scopus.com/inward/record.url?scp=84862492483&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84862492483&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0039365

DO - 10.1371/journal.pone.0039365

M3 - Article

C2 - 22724005

AN - SCOPUS:84862492483

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 6

M1 - e39365

ER -